Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …

Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago
remain major prognostic factors. In recent years, the introduction of cutting-edge genomic …

In this study, targeted sequencing to screen 50 multidrug refractory multiple myeloma (rMM)
patients was performed by using the Multiple Myeloma Mutation Panel. Patients were …

Multiple myeloma (MM) is a plasma cell malignancy preceded by a premalignant stage,
named monoclonal gammopathy of undetermined significance (MGUS), and often a …

In multiple myeloma, next-generation sequencing (NGS) has expanded our knowledge of
genomic lesions, and highlighted a dynamic and heterogeneous composition of the tumor …

Although survival of multiple myeloma patients has at least doubled during recent years,
most patients eventually relapse, and treatment at this stage may be particularly complex. At …

Despite an increasing number of approved therapies, multiple myeloma (MM) remains an
incurable disease and only a small number of patients achieve prolonged disease control …

Inhibition of the AAA ATPase, p97, was recently shown to be a novel method for targeting
the ubiquitin proteasome system, and CB-5083, a first-in-class inhibitor of p97, has …

Cereblon (CRBN), a target of immunomodulatory drugs (IMiD), forms the CRL4CRBN E3
ubiquitin ligase (CRL4) complex with DDB1, CUL4B and ROC1. 1, 2 Under the influence of …

Myeloma is characterized by extensive inter-patient genomic heterogeneity due to multiple
different initiating events. A recent multi-region sequencing study demonstrated spatial …